Division of Gastroenterology and Hepatology, St Louis University School of Medicine, St Louis, MO 63110-0250, USA.
Clin Liver Dis. 2011 Aug;15(3):573-83. doi: 10.1016/j.cld.2011.05.001.
Individuals infected with hepatitis C virus (HCV) are at risk for cirrhosis and/or hepatocellular carcinoma. Treatment of HCV infection has undergone several revisions over the past 15 years and continues to evolve. The current major advance is with the protease inhibitors in addition to pegylated interferon and ribavirin. The emergence of resistance needs to be monitored carefully as newer and more potent drugs are added to the interferon and ribavirin backbone drugs. In addition, adverse events will be more frequent and some novel ones will require special attention.
感染丙型肝炎病毒（HCV）的个体存在肝硬化和/或肝细胞癌的风险。在过去的 15 年中，HCV 感染的治疗经历了多次修订，并且仍在不断发展。目前的主要进展是在聚乙二醇干扰素和利巴韦林的基础上增加蛋白酶抑制剂。随着更多新型、更有效的药物加入到干扰素和利巴韦林的基础药物中，需要密切监测耐药性的出现。此外，不良事件的发生将更加频繁，一些新的不良事件将需要特别关注。
